🇺🇸 FDA
Pipeline program

pembrolizumab/vibostolimab

7684A-006

Phase 3 mab active

Quick answer

pembrolizumab/vibostolimab for Carcinoma, Non-Small-Cell Lung is a Phase 3 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck KGaA, Darmstadt, Germany
Indication
Carcinoma, Non-Small-Cell Lung
Phase
Phase 3
Modality
mab
Status
active

Clinical trials